FAES FARMA SA financials
FAES FARMA SA
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
959800FXZQY7U3P1G969 Financial statements
(EUR, as reported — unscaled; 105 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €493.6M | €451.2M |
| Other income | €16.4M | €21.9M |
| Employee benefits expense | €104.9M | €96.6M |
| Raw materials & consumables used | €173.2M | €157.9M |
| Depreciation & amortisation | €20.3M | €19.4M |
| Finance costs | €1.2M | €1.0M |
| Profit before tax | €107.6M | €102.9M |
| Income tax expense | -€3.5M | €11.2M |
| Profit for the year | €111.1M | €91.7M |
| — attributable to owners | €111.4M | €91.9M |
| — attributable to NCI | -€246.0K | -€209.0K |
| Total comprehensive income | €111.8M | €93.9M |
| Per share | ||
| Basic EPS | €0.36 | €0.30 |
| Diluted EPS | €0.36 | €0.30 |
| Free cash flow / share | €0.26 | €0.02 |
| Cash flow statement | ||
| Cash generated from operations | €126.7M | €109.0M |
| Net cash from operating activities | €115.5M | €101.0M |
| Net cash from investing activities | -€34.2M | -€97.4M |
| Purchase of PP&E (capex) | €33.8M | €95.8M |
| Purchase of intangibles | €5.8M | €6.4M |
| Net cash from financing activities | -€51.7M | -€35.4M |
| Dividends paid | €48.2M | €14.6M |
| Repayments of borrowings | €3.5M | €3.3M |
| Balance sheet | ||
| Total assets | €853.1M | €776.6M |
| Non-current assets | €519.4M | €486.3M |
| Property, plant & equipment | €295.4M | €274.1M |
| Right-of-use assets | €5.5M | €6.5M |
| Current assets | €333.7M | €290.3M |
| Inventories | €142.5M | €129.0M |
| Trade & other receivables | €119.1M | €113.5M |
| Cash & equivalents | €64.2M | €34.6M |
| Total equity | €726.6M | €663.4M |
| — attributable to owners | €725.9M | €662.4M |
| Non-controlling interests | €748.0K | €994.0K |
| Non-current liabilities | €23.0M | €25.9M |
| Lease liabilities (non-current) | €2.7M | €4.4M |
| Current liabilities | €103.5M | €87.3M |
| Trade & other payables | €71.3M | €56.0M |
| Deferred tax liabilities | €15.6M | €16.9M |
| Derived metrics | ||
| Free cash flow | €81.7M | €5.2M |
| Net margin | 22.5% | 20.3% |
| Return on equity | 15.3% | 13.8% |
| Cash conversion ratio | 1.04× | 1.10× |
| Capex coverage | 3.41× | 1.05× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €20.3M | €19.4M |
| Adjustments For Decrease Increase In Inventories | -€13.5M | -€13.3M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€8.0M | €936.0K |
| Adjustments For Finance Income | €1.7M | €1.1M |
| Adjustments For Finance Income Cost | -€433.0K | -€383.0K |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -€362.0K | -€273.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €359.0K | €74.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | -€470.0K | -€301.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | €1.3M | €607.0K |
| Adjustments For Income Tax Expense | -€3.5M | €11.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | €16.1M | -€1.4M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €1.1M | €0 |
| Adjustments For Provisions | €2.9M | €2.1M |
| Adjustments For Reconcile Profit Loss | €134.6M | €126.0M |
| Adjustments For Sharebased Payments | €747.0K | €774.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €769.0K | €659.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €4.5M |
| Changes In Inventories of Finished Goods and Work In Progress | -€6.1M | -€3.8M |
| Comprehensive Income Attributable To Owners of Parent | €112.0M | €94.1M |
| Current Tax Liabilities Current | €3.6M | €3.4M |
| Deferred Tax Assets | €32.5M | €19.0M |
| Dividends Recognised As Distributions To Owners Per Share | €0.04 | — |
| Equity and Liabilities | €853.1M | €776.6M |
| Finance Income | €1.7M | €1.1M |
| Gains Losses On Exchange Differences On Translation Net of Tax | €636.0K | €2.2M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €1.4M | €26.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €12.5M | €8.7M |
| Increase Decrease In Cash and Cash Equivalents | €29.6M | -€31.8M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | €322.0K | €221.0K |
| Increase Decrease Through Treasury Share Transactions | — | -€17.7M |
| Inflows of Cash From Investing Activities | €13.1M | €18.2M |
| Interest Paid Classified As Operating Activities | €433.0K | €383.0K |
| Interest Received Classified As Operating Activities | €1.7M | €1.1M |
| Investment Property | €1.6M | €1.6M |
| Issue of Equity | — | €0 |
| Issued Capital | €31.6M | €31.6M |
| Lease Liabilities | €3.1M | €2.2M |
| Liabilities | €126.5M | €113.2M |
| Noncurrent Government Grants | €1.1M | €241.0K |
| Noncurrent Provisions | €946.0K | €864.0K |
| Other Adjustments To Reconcile Profit Loss | €873.0K | €206.0K |
| Other Comprehensive Income | €636.0K | €2.2M |
| Other Current Financial Assets | €7.9M | €13.1M |
| Other Current Financial Liabilities | €17.9M | €18.4M |
| Other Expense By Nature | €109.2M | €100.3M |
| Other Inflows Outflows of Cash Classified As Financing Activities | €0 | €260.0K |
| Other Inflows Outflows of Cash Classified As Operating Activities | -€2.5M | -€3.2M |
| Other Noncurrent Financial Assets | €178.0K | €336.0K |
| Other Noncurrent Financial Liabilities | €2.6M | €3.5M |
| Other Reserves | €509.9M | €489.7M |
| Other Shortterm Provisions | €7.6M | €7.3M |
| Outflows of Cash From Investing Activities | €7.8M | €8.8M |
| Payments of Other Equity Instruments | €0 | €17.7M |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | €69.0K | €0 |
| Profit Loss From Continuing Operations | €111.1M | €91.7M |
| Reduction of Issued Capital | — | €0 |
| Reserve of Exchange Differences On Translation | -€2.4M | -€3.1M |
| Retained Earnings | €209.0M | €165.8M |
| Share Premium | €1.5M | €1.5M |
| Treasury Shares | €11.0M | €11.0M |
Methodology
Every line item above is a fact tagged in FAES FARMA SA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.